Dupixent®(dupilumab) - Expanded indication
June 7, 2022 - Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab), for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Top